Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY: NNVC )

1.120 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Jan 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,582
Open 1.120
Bid (Size) 1.120 (6)
Ask (Size) 1.170 (29)
Prev. Close 1.120
Today's Range 1.120 - 1.120
52wk Range 1.010 - 3.590
Shares Outstanding 14,347,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Broad-Spectrum Antiviral Innovations at Biotech Showcase 2025
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
Via ACCESSWIRE

Performance

YTD
-21.13%
-21.13%
1 Month
-25.83%
-25.83%
3 Month
-24.83%
-24.83%
6 Month
-49.09%
-49.09%
1 Year
+7.69%
+7.69%

More News

Read More
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as a Broad-Spectrum Antiviral Solution to Emerging Threats
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
Via ACCESSWIRE
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Touts NV-387 as Key Defense Against Potential Bird Flu Pandemic
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
Via ACCESSWIRE
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financial Progress and Advances Towards Key Phase II Clinical Trials
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Advancements at Spartan Capital Investors Conference
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform and Drug Delivery Advances at PODD Conference
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides President Dr. Diwan to Present at the PODD Conference
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) CEO Featured in Latest Episode of PODD Podcast
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR Summit
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K
Via Investor Brand Network
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
Via ACCESSWIRE
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
Via ACCESSWIRE
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
Via ACCESSWIRE
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
Via ACCESSWIRE
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
Via FinancialNewsMedia
Exposures COVID-19
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.